Business Description
Arch Biopartners is a Toronto-based Canadian company working to bring new medicines to patients with serious kidney conditions. Its most advanced treatment, LSALT Peptide, is currently being tested in Phase 2 clinical trials to address kidney damage caused by inflammation in heart surgery patients. The company is also developing cilastatin to protect kidneys from toxin-related harm, as well as a separate program focused on chronic kidney disease.
